Recent presentations to brokers and analysts have brought out...

Recent presentations to brokers and analysts have brought out some interesting statements from the normally very cautious, and restrained, senior management from CST.

Two points stand out:

1. Sales, which have doubled in each of the last four years, are expected to double again in each of the next three years. Since this year looks likely to exceed $20m sales, that means that we can look forward to $160m sales in three years time (with excellent profit margins).

2. The only other competition, world-wide, to replace the century-old skin test for TB, (T-Spot, from Oxford Immunotech), is achieving almost zero sales (about 30 per month).

Sounds like big revenue, protected by wide, Buffet-style, moats.

Regards, Prime